Compare metabolites in 2 of these studies:
Study A:   Study B:  

List of Studies ( Metabolite:18-HETE)

Study_idAnalysis_idStudy_titleSourceSpeciesDiseaseInstituteUnits(range)
ST001680 AN002738 Metabolome of NAFLD in high fat diet mouse model Liver Mouse Fatty liver disease Weill Cornell Medicine Abundance
ST002455 AN004005 Organism-Wide Analysis of Sepsis Reveals Mechanisms of Systemic Inflammation Blood Mouse Sepsis University of Chicago intensity
ST001951 AN003176 Quantification of ω-3 fatty acids and their derivatives in lungs from hypoxia-induced pulmonary hypertension (PH) mice. Lung Mouse Pulmonary hypertension University of Tokyo ng/mg tissue
ST000004 AN000004 Lipidomics studies on NIDDK / NIST human plasma samples Blood Human LIPID MAPS nM
ST000916 AN001491 Biomarkers of NAFLD progression: a lipidomics approach to an epidemic. Part 2:Plasma Blood Human Fatty liver disease LIPID MAPS nM
ST003050 AN005001 Plasma instead of serum avoids critical confounding of clinical metabolomics studies by platelets (Part 1) Blood Human University of Vienna normalized AUC
ST001206 AN002008 Effects of cold exposure on serum lipidomic in mice Blood Mouse Joslin Diabetes Center - Harvard Medical School Peak area
ST001207 AN002009 Lipidomics in the serum of cold exposed mice treated with 12-LOX inhibitor LOXBlock-1 Blood Mouse Joslin Diabetes Center - Harvard Medical School Peak area
ST001213 AN002024 Serum lipidomic profile of cold-exposed Ucp1cre/12-LOX KO mice Blood Mouse Joslin Diabetes Center - Harvard Medical School Peak area
ST001214 AN002025 Lipidommics in the serum of human subjects Blood Human Joslin Diabetes Center - Harvard Medical School Peak area
ST001215 AN002026 Effect of Mirabegron Treatment on serum lipidome Blood Human Joslin Diabetes Center - Harvard Medical School Peak area
ST000915 AN001485 Biomarkers of NAFLD progression: a lipidomics approach to an epidemic. Part 2:Liver Liver Human Fatty liver disease LIPID MAPS pmol/mg
  logo